Trials / Completed
CompletedNCT03417778
Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function
A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics of Filgotinib in Subjects With Impaired Hepatic Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of filgotinib and its metabolite, GS-829845, in participants with varying degrees of impaired hepatic function relative to matched, healthy controls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Filgotinib | 100 mg tablet administered orally |
Timeline
- Start date
- 2018-04-03
- Primary completion
- 2018-08-09
- Completion
- 2018-08-09
- First posted
- 2018-01-31
- Last updated
- 2021-01-15
- Results posted
- 2021-01-15
Locations
4 sites across 3 countries: United States, Germany, New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03417778. Inclusion in this directory is not an endorsement.